Brendan Moran

9PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMachine learning not elsewhere classifiedLiquid biopsiesPublic policy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 18, 2026
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be safely combined with nephrectomy in patients with appendiceal malignancy and synchronous renal cell carcinoma.

|Mar 26, 2026
Impact of Time Between Multidisciplinary Team Meeting Discussion and Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastases on Surgical, Quality of Life and Survival Outcomes.

Wilson Jiang, Cherry Koh, Michael Solomon

|Dec 30, 2024
Reported outcomes following cytoreductive surgery for colorectal peritoneal metastases: A systematic review to inform evidence-based practice and international consensus.

Pratik Raichurkar, Kilian Brown, Cherry Koh

|Mar 30, 2024
Specialization improves rectal cancer management: humans not machines determine optimal outcome.

Brendan John Moran, Soren Laurberg

|Jan 04, 2024
The Pelican OReCO (optimizing rectal cancer outcomes) programme in collaboration with ACPGBI 'decisions, incisions, technology'.

Brendan Moran, Jared Torkington

|Dec 22, 2023
Response to: Boyle J M, et al. 'What is the impact of hospital and surgeon volumes on outcomes in rectal cancer surgery?' Colorectal Disease 2023; 25: 1981-1993.

Justin Davies, Mark Cheetham, Graham Branagan

Pageof 2

Frequent Collaborators

2 joint publications

Michael Solomon

1 joint publications

Glen R Guerra

1 joint publications

Siu Y Kok

1 joint publications

Faheez Mohamed